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Abstract 
Secretory leukocyte protease inhibitor (SLPI) is an important respiratory tract host defence 
protein which is proteolytically inactivated by excessive neutrophil elastase (NE) during 
chronic Pseudomonas infection in the cystic fibrosis (CF) lung. We generated two putative 
NE-resistant variants of SLPI by site-directed mutagenesis, SLPI-A16G and SLPI-S15G-A16G, 
with a view to improving SLPI’s proteolytic stability. Both variants showed enhanced 
resistance to degradation in the presence of excess NE as well as CF patient sputum 
compared to SLPI-wild type (SLPI-WT). The ability of both variants to bind bacterial LPS and 
interact with NF-κB DNA binding sites was also preserved. Finally, we demonstrate increased 
anti-inflammatory activity of the SLPI-A16G protein compared to SLPI-WT in a murine model 
of pulmonary Pseudomonas infection. This study demonstrates the increased stability of 
these SLPI variants compared to SLPI-WT and their therapeutic potential as a putative anti-
inflammatory treatment for CF lung disease. 
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Introduction 
Chronic lung infection, inflammation, and gradual destruction of the lung are characteristic 
clinical features of cystic fibrosis (CF). This gradual loss of lung function is fatal to most CF 
patients as over 95% die of respiratory failure. Neutrophils play a leading role in the 
destruction of the lung tissue in CF 1–3. Infection by particularly resistant pathogens such as 
Pseudomonas aeruginosa 4 causes impairment of host immune defense mechanisms 
triggering a sustained pro-inflammatory environment and the recruitment of neutrophils in 
high numbers to the CF airways 5. As a consequence of this accumulation of neutrophils, 
elevated levels of proteases, such as neutrophil elastase (NE), are found in the CF airways 6,7. 
NE is regarded as a key driver of lung destruction 8,9 and inflammation especially during 
chronic P. aeruginosa infection in the CF lung 10,11. 
Consequently, the development of NE inhibitors has been a major research focus. 
Small molecule inhibitors such as L-658,758 12 as well as protein-based inhibitors of NE such 
as EPI-hNE4/DX-890 13,14 have been developed for this purpose. Naturally occurring 
inhibitors such as α-1 antitrypsin, SLPI, elafin and monocyte/neutrophil elastase inhibitor 
(MNEI) have also attracted a lot of interest. They have a broad protease inhibition spectrum, 
which is clearly beneficial in the context of CF lung disease where many different proteases 
are involved in the degradation of the lung tissue. In addition, some of these natural 
antiproteases have other properties which could contribute to the reduction of lung tissue 
degradation. SLPI and elafin for instance have been demonstrated to possess antibacterial as 
well as anti-inflammatory properties 15–18.  
One major limitation to the use of natural antiproteases as therapeutic drugs for the 
treatment of CF lung disease is their susceptibility to cleavage by proteases 19,20. In the CF 
lung where protease levels are very high, many endogenous protease inhibitors are found in 
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a cleaved, inactive form 10,11. Engineering antiproteases to make them resistant to 
proteolytic degradation could be a way of enhancing their therapeutic profile to a sufficient 
level to turn them into marketed drugs. 
 SLPI, a member of the lung antiprotease screen particularly abundant in the upper 
airways and a potent inhibitor of NE 21, was demonstrated to be cleaved by NE in its N-
terminal domain at positions Ser15-Ala16 and Ala16-Gln17, in the lungs of CF patients infected 
with P. aeruginosa 10. In this study, we have developed new ways to improve SLPI’s stability 
which may improve its therapeutic potential for the treatment of CF lung inflammation. 
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Results 
Design of SLPI variants resistant to cleavage by neutrophil elastase 
The determination of the NE cleavage site at positions Ser15-Ala16 and Ala16-Gln17 in the 
amino acid sequence of human SLPI-WT by Weldon et al. 10, paved the way for the design of 
SLPI variants resistant to degradation by this protease. Taking advantage of the key role 
played by the amino acid at the P1 position of a protease cleavage site in the determination 
of the susceptibility of the substrate to cleavage by the protease 22, variants resistant to 
cleavage by a given protease can be conveniently engineered by a simple change of the 
amino acid at the P1 position of the cleavage site 23. The MEROPS database 24 provides a list 
of NE substrates and their amino acid composition at the cleavage site. This information was 
used to select the amino acids best suited to replace those at the P1 positions of the NE 
cleavage sites in the SLPI sequence. Two amino acids, tryptophan and histidine, were never 
found at the P1 position of the cleavage site in the 482 NE substrates listed in the MEROPS 
database. However, we selected glycine (only found to be present at the P1 of a NE 
substrate in two occurrences; Figure 1A) to replace serine and alanine at the P1 position of 
the two NE cleavage sites in the SLPI amino acid sequence, owing to a reduced likelihood of 
disruption of the overall protein conformation with this amino acid. Two SLPI variants were 
engineered by site-directed mutagenesis. As illustrated in Figure 1B, the first variant (SLPI-
A16G) has a glycine residue instead of an alanine residue at the P1 position of the preferred 
Ala16-Gln17 NE cleavage site 10. In the second variant (SLPI-S15G-A16G), the amino acids at 
the P1 positions of the two NE cleavage sites were replaced by glycine residues. 
 
Expression and purification of recombinant SLPI-WT and SLPI-A16G and SLPI-S15G-A16G 
variants 
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SLPI-WT and its SLPI-A16G and SLPI-S15G-A16G variants were expressed in a bacterial 
system, using M15 [pREP4] Escherichia coli cells as a host and pQE30 as an expression 
vector. In this system, the recombinant proteins were expressed with an N-terminal His6-tag 
for convenient purification by immobilized metal ion affinity chromatography (IMAC). After 
purification, all three recombinant proteins were isolated in similar yields (1.3 – 1.9 mg per 
liter of culture). SLPI-WT and its two variants gave bands of the expected molecular weight 
(ca. 13 kDa) when analysed by SDS-PAGE and could be detected by both anti-SLPI and anti-
His antibodies by Western blotting, confirming the integrity of the proteins (Figure 2). The 
purity of all three proteins was confirmed by SDS-PAGE analysis followed by staining with 
Coomassie Brilliant Blue (Figure 2A). Identity was also confirmed by Western blotting with 
anti-SLPI and anti-His antibodies (Figure 2B-C). 
 
Inhibition of NE by SLPI-A16G and SLPI-S15G-A16G variants 
To determine if the mutations engineered in SLPI amino acid sequence had any effect on its 
antiprotease activity, an NE activity assay was carried out where recombinant SLPI-WT, SLPI-
A16G and SLPI-S15G-A16G were incubated at 37°C with NE in the presence of a fluorogenic 
peptide substrate specific for NE. All proteins were able to fully inhibit NE in similar molar 
ratios (data not shown).  
Interaction of SLPI variants with NF-κB DNA binding sites 
The ability to bind and block NF-κB DNA binding sites in the promoter regions of target genes 
involved in the inflammatory response is an important mechanism through which SLPI exerts 
its anti-inflammatory properties 25. Previous work has demonstrated that this ability is 
abrogated following cleavage of SLPI by NE 10. To determine if the mutations engineered in 
SLPI amino acid sequence had any effect on its ability to bind to NF-κB DNA binding sites, 
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SLPI-WT, SLPI-A16G and SLPI-S15G-A16G variants were incubated with an NF-κB consensus 
oligonucleotide and the formation of SLPI:DNA complexes was monitored by EMSA. Bands 
corresponding to SLPI:DNA complexes were detected for all three recombinant proteins, 
suggesting that the variants retained the ability to bind to NF-κB DNA binding sites and 
interfere with pro-inflammatory pathways (Figure 3). 
 
Binding of SLPI variants to P. aeruginosa LPS 
The binding of SLPI to bacterial LPS and the possible ensuing disruption of the bacterial 
membrane are thought to be responsible for SLPI anti-bacterial properties 26. This ability to 
bind LPS is lost upon cleavage of SLPI by NE 10. To see if the mutations engineered in the SLPI 
amino acid sequence could have affected its ability to bind bacterial LPS, the binding of all 
three recombinant proteins to P. aeruginosa LPS was tested by indirect ELISA. SLPI-A16G and 
SLPI-S15G-A16G variants as well as SLPI-WT all showed a dose-dependent binding to P. 
aeruginosa LPS, suggesting that the mutations in the SLPI amino acid sequence did not alter 
its capacity to interact with bacterial LPS (Figure 4).  
 
 
Effects of excesses of NE and CF sputum on recombinant SLPI-WT and SLPI-A16G and SLPI-
S15G-A16G variants 
To determine if the SLPI variants were resistant to degradation by NE, equal amounts of 
active recombinant SLPI-WT, SLPI-A16G and SLPI-S15G-A16G were incubated with a 10-fold 
molar excess of NE at 37°C and samples were taken at various timepoints and analysed by 
SDS-PAGE and Western blotting with both anti-SLPI and anti-His antibodies. Recombinant 
SLPI-WT was quickly degraded in the presence of an excess of NE (Figure 5A). Both SLPI-
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A16G and SLPI-S15G-A16G mutants proved much more resistant to degradation by NE with 
only partial cleavage of SLPI-S15G-A16G evident (Figure 5A). To further demonstrate the 
clinical relevance of the two SLPI variants, equal amounts of active recombinant SLPI-WT, 
SLPI-A16G and SLPI-S15G-A16G were incubated with CF patient sputum. As in experiments 
involving incubation with purified NE, recombinant SLPI-WT was quickly degraded (Figure 
5B). The two SLPI variants proved again more resistant to degradation by CF patient sputum 
than recombinant SLPI-WT and significant amounts of protein could be still be detected 
following incubation (Figure 5B). The density of each SLPI band was evaluated using 
densitometry and confirmed a greater decrease of the SLPI-WT protein compared to SLPI-
A16G and SLPI-S15G-A16G following incubation with NE (Figure 5C) or CF sputum (Figure 
5D). 
 
Effect of SLPI-WT and SLPI-A16G in an in vivo model of pulmonary infection 
We have previously demonstrated significant cleavage of SLPI by NE in the lungs of CF 
patients infected with P. aeruginosa 10. Following on from our experiments in Figure 5 
demonstrating increased resistance of SLPI-A16G to cleavage by NE and CF sputum 
compared to SLPI-WT, we tested the effect of both proteins in an in vivo model of pulmonary 
infection induced by instillation of a clinical strain of P. aeruginosa isolated from the lungs of 
a patient with CF. SLPI-A16G was chosen over SLPI-S15G-A16G as it appeared to be more 
stable in incubations with NE and pooled CF sputum. Although we did not demonstrate a 
reduction in bacterial counts in the mice treated with SLPI-WT and SLPI-A16G versus 
untreated mice (data not shown), we did observe a significant decrease in neutrophil 
recruitment to the lungs of mice treated with SLPI-A16G versus mice instilled with P. 
aeruginosa alone (Figure 6A). In contrast, mice treated with SLPI-WT did not exhibit a 
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decrease in lung neutrophil recruitment (Figure 6A). To explain this decrease in neutrophil 
recruitment, we measured serum levels of the neutrophil chemoattractant KC (Figure 6B). 
KC levels were significantly decreased in the serum of mice treated with SLPI-A16G but not 
in the serum of mice treated with SLPI-WT. Other cytokines/chemokines were measured in 
lung homogenate (supplementary Figure 1 - TNF, IL1, IL6, KC and MIP-2) and serum 
(supplementary Figure 2 –  IL1, IL6 and MIP-2) but were shown not to be significantly 
decreased in Pseudomonas-infected SLPI-WT versus SLPI-AG groups. 
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Discussion 
SLPI has previously been used in a clinical study in CF patients leading to reduced NE activity 
and neutrophil levels in the lungs of these patients 27. However, we have previously shown 
that during Pseudomonas infection in the CF lung, elevated levels of NE are responsible for 
the proteolytic cleavage of SLPI 10. Two NE cleavage sites in SLPI were identified between 
residues Ser15-Ala16 and between Ala16-Gln17. Based on this information, we designed 
variants of SLPI that we hypothesised would be more resistant to degradation by NE, 
speculating that this could perhaps improve SLPI’s potential as a therapeutic. We introduced 
substitutions into the SLPI sequence at the NE cleavage sites to reduce cleavage 
susceptibility. The resulting proteins (SLPI-A16G and SLPI-S15G-A16G) were successfully 
more resistant to cleavage by NE and Pseudomonas-infected CF sputum, and, in addition 
retained many of the features of native SLPI.  
With the use of the Pseudomonas infection model of lung inflammation, we have 
demonstrated that the SLPI-A16G variant displayed enhanced anti-inflammatory properties 
when compared to the native SLPI-WT protein, as indicated by a significant reduction in 
inflammatory cells within the lungs, specifically, neutrophils. Neutrophilic influx to the 
respiratory tract is characteristic of the initial stages of acute pulmonary infection and is 
associated with disruption of the alveolar-capillary barrier and lung tissue damage 28,29. 
Bacterial infection is known to upregulate the expression of key neutrophil chemokines 
including KC and MIP-2. However, in this current investigation, we noted that only KC levels 
were significantly reduced in mice treated with the SLPI-A16G mutant which was not the 
case in mice treated with SLPI-WT. Other key chemokines and cytokines (TNF-α, MIP-2, IL-6, 
IL-1β) were not reduced in mice treated with either SLPI-A16G or SLPI-WT (data not shown). 
We postulate that this reduction in KC levels in mice treated with SLPI-A16G may be related 
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to the enhanced cleavage resistance and therefore sustained anti-inflammatory effect of this 
variant compared to the native SLPI-WT protein.  
We have previously demonstrated that native recombinant SLPI can inhibit LPS-
induced IL-8 production by macrophages, but in our in vivo infection model this anti-
inflammatory effect of native SLPI is not evident, most likely due to the proteolytic 
degradation of SLPI by increased levels of NE. We have observed similar effects when we 
mutated the SLPI-related WFDC protein, elafin, to enhance its stability. In that study, we 
found that a more NE-resistant variant of elafin (GG-elafin) could also significantly reduce 
neutrophil recruitment in a mouse model of LPS-induced lung inflammation compared to 
wild type elafin 30. However, in contrast to the current SLPI study, we found that GG-elafin 
did not reduce KC levels. This may be related to the fact that SLPI and elafin have different 
anti-inflammatory effects. However, it may also be due to the use of different models of 
inflammation in the two studies – Pseudomonas-induced inflammation versus LPS-induced 
inflammation.  
One of the limitations of this study is the use of an acute lung infection model to 
replicate what happens in a chronic lung infection-based disease such as CF. Future studies 
may involve evaluation of SLPI-A16G and SLPI-WT in a relevant chronic inflammation model 
such as the βENaC-transgenic model which reproduces many of the features of CF-like lung 
disease 31. Another unexpected effect of SLPI-WT and SLPI-A16G in this study was the 
absence of any reduction in CFUs in the in vivo model of infection. SLPI has previously been 
shown to display antibacterial activity against Gram negative bacteria such as P. aeruginosa 
32. However, to our knowledge, SLPI’s antibacterial activity in in vivo models of lung infection 
has not been evaluated and there may be no effect of SLPI against bacteria in vivo. 
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Overall, our findings indicate that the SLPI-A16G and SLPI-S15G-A16G variants that 
we have engineered are more resistant to protease degradation, whilst retaining 
antiprotease and anti-inflammatory properties similar to the SLPI-WT protein. These SLPI 
variants may hold enhanced therapeutic potential. In particular we have shown that SLPI-
A16G may be of therapeutic benefit in reducing the potentially damaging inflammatory 
response to infection in the lung, as demonstrated by its increased effectiveness in a murine 
model of pulmonary infection compared to the proteolytically sensitive SLPI-WT protein. 
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Methods 
Cloning of SLPI variants 
pET32c-SLPI was a kind gift from Dr. André Cantin (University of Sherbrook, Canada). The 
DNA sequence encoding for human wild-type SLPI was cloned into the KpnI and HindIII 
restriction sites of the pQE30 expression vector (Qiagen, Manchester, UK) and this plasmid is 
referred to as pQE30-SLPI-WT. For each SLPI variant, the synthesis of the mutant strand was 
performed by PCR using 25 ng of pQE30-SLPI-WT plasmid, 125 ng of the relevant forward 
and reverse primers (Table 1), 2.5 U of PfuTurbo DNA polymerase and 1 µl of dNTP mix and 5 
µl of 10 x reaction buffer as required in a final volume of 50 µl as per (Quik-site Directed 
Mutagenesis kit, Agilent Technologies LDA UK Limited, Stockport, UK). This mix was then 
subjected to PCR under the conditions of 30 s at 95°C; 16 cycles of 30 s at 95°C, 1 min at 
55°C, and 4 min 30 s at 68°C. After cooling down the reaction to 37°C, 10 U of DpnI (New 
England Biolabs, Hitchin, UK) were added to the PCR mix and the parental strands were 
digested at 37°C for 1 h. The digestion products were then used to transform E. coli XL1-Blue 
supercompetent cells (Agilent Technologies LDA UK Limited, Stockport, UK). The success of 
the site-directed mutagenesis was verified by DNA sequencing and, for each SLPI variant, a 
single clone was used for all subsequent experiments. The plasmids encoding for the SLPI 
variants SLPI-A16G and SLPI-S15G-A16G are referred to as pQE30-SLPI-A16G and pQE30-
SLPI-S15G-A16G, respectively. 
 
Expression of SLPI-WT, SLPI-A16G and SLPI-S15G-A16G variants in M15 [pREP4] E. coli 
M15 [pREP4] E. coli cells (Qiagen, Manchester, UK) were transformed with the pQE30-SLPI-
WT, pQE30-SLPI-A16G and pQE30-SLPI-S15G-A16G plasmids and grown overnight with 
shaking at 37°C in Luria-Bertani (LB) medium (5 ml) supplemented with 100 µg/ml ampicillin 
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and 25 µg/ml kanamycin (Sigma-Aldrich, Dorset, UK). These overnight cultures (2.5 ml) were 
used to inoculate LB (500 ml) supplemented with 100 µg/ml ampicillin and 25 µg/ml 
kanamycin and pre-warmed to 37°C. The cultures were grown with shaking at 37°C until OD 
600 reached 0.6. Expression of the recombinant proteins was then induced with IPTG (1 mM 
final concentration). The cultures were incubated at 37°C with shaking for another 4 h 
before the cells were harvested by centrifugation (4,000 rpm for 30 min at 4°C). Cells pellets 
awaiting purification were stored at - 80°C. 
 
Purification of SLPI-WT, SLPI-A16G and SLPI-S15G-A16G 
Cell pellets were thawed on ice then resuspended in lysis buffer (40 ml) containing 8 M urea, 
1 mM β-mercaptoethanol, 500 mM NaCl, 5 mM imidazole and 20 mM sodium phosphate, pH 
8.0. The cells were lysed for 2 h at room temperature with shaking. The cell lysates were 
clarified by centrifugation (4,500 x g for 1 h) followed by filtration of the supernatants 
through 0.2 µm filter disks. HiTrap™ Chelating HP columns (1 ml) (GE Healthcare Life 
Sciences, Little Chalfont, UK) were mounted on AKTAprime™ chromatography systems (GE 
Healthcare Life Sciences, Little Chalfont, UK), charged with Ni2+ ions and equilibrated with a 
buffer containing 8 M urea, 1 mM β-mercaptoethanol, 500 mM NaCl, 5 mM imidazole and 
20 mM sodium phosphate, pH 8.0. The clarified cell lysates were loaded onto the columns at 
1 ml/min. Non-specifically bound material was washed off the column at 1 ml/min with 10 
column volumes of buffer containing 8 M urea, 1 mM β-mercaptoethanol, 500 mM NaCl, 5 
mM imidazole and 20 mM sodium phosphate, pH 8.0. The denatured recombinant proteins 
bound onto the column were refolded on-column at a flow rate of 0.5 ml/min by gradually 
removing the urea from the buffer over 15 column volumes. The refolded recombinant 
proteins bound to the column were then washed at 1 ml/min with 10 column volumes of 
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buffer containing 500 mM NaCl, 5 mM imidazole, 20 mM sodium phosphate, pH 8.0 and 1 
mM β-mercaptoethanol. Refolded recombinant proteins were eluted off the column at 1 
ml/min by increasing the concentration of imidazole from 5 mM to 500 mM in 20 column 
volumes. Elution fractions (1 ml) were collected and analysed by SDS-PAGE followed by 
Coomassie staining. Fractions containing SLPI-WT or its SLPI-A16G and SLPI-S15G-A16G 
variants were pooled and dialysed at 4°C with gentle agitation against 10 volumes of PBS pH 
7.4 with two changes of dialysis buffer. The concentrations of the purified recombinant 
proteins were determined by BCA assay according to the manufacturer’s instructions (Pierce 
BCA Assay, Fisher Scientific UK, Leicestershire). 
 
Characterisation of purified SLPI-WT, SLPI-A16G and SLPI-S15G-A16G variants by SDS-PAGE 
Purified dialysed SLPI-WT and its SLPI-A16G and SLPI-S15G-A16G variants were analysed by 
SDS-PAGE on 15% (w/v) polyacrylamide gels under reducing Laemmli conditions. Gels were 
stained with Coomassie Brilliant blue for total protein analysis. For Western blotting, gels 
were transferred onto nitrocellulose membrane and the membranes blocked with 3% (w/v) 
BSA in PBS containing 0.1% (v/v) Tween 20 for 1 h at room temperature. Probing was carried 
out  with a biotinylated anti-SLPI antibody (1:500 dilution; R&D Systems, Abingdon, UK) 
followed by incubation with streptavidin conjugated horseradish peroxidase (HRP) (1:2,500 
dilution; BioLegend, London UK) in 3% BSA (w/v) PBS containing 0.1% Tween 20 or with 
rabbit anti-His antibody (1:1,000 dilution; Insight Biotechnology Ltd., Wembley, UK)  
followed by incubation with HRP conjugated goat anti-rabbit antibody (1:10,000 dilution; 
Insight Biotechnology Ltd., Wembley, UK). Peroxidase activity was detected using a 
chemiluminescent substrate (GE Healthcare, Buckinghamshire, UK) and analysed using the 
Syngene G:Box and GeneSnap software (SynGene UK, Cambridge).  
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Neutrophil elastase inhibition assays 
Neutrophil elastase (NE; 100 ng; Elastin Products Company, Missouri, USA) was incubated 
for 10 min at 37°C alone or with different amounts of recombinant SLPI-WT, SLPI-A16G or 
SLPI-S15G-A16G variant in 80 µl (final volume) of 0.5 M NaCl, 100 mM HEPES pH 7.5, 0.1% 
(v/v) Brij 97. After addition of 20 µl of N-(methoxysuccinyl)-Ala-Ala-Pro-Val-7-amino-4-
methylcoumarin (AAPV-AMC; 100 µM final concentration; Enzo Life Sciences, Exeter, UK), NE 
activity was monitored by detecting the release of the fluorescent AMC cleavage product 
(excitation at 360 nm ; emission at 465 nm)  for 12 min at 37°C using a 96-well microplate 
reader (Synergy HT using Gen5™ software, BioTek, Bedfordshire, UK). The change in relative 
fluorescence units over a 12 min period were calculated for all samples and the results 
expressed as percentage of non-inhibited NE. 
 
 
 
EMSA 
The binding of SLPI-WT and the SLPI-A16G and SLPI-S15G-A16G variants to an NF-κB 
consensus DNA binding site was assessed by Electrophoretic Mobility Shift Assay (EMSA) as 
described previously 10,25. Recombinant SLPI-WT and SLPI-A16G and SLPI-S15G-A16G variants 
(1 µg) were incubated with double-stranded biotinylated NF-κB consensus oligonucleotide 
5’-AGTTGAGGGGACTTTCCCAGGC-3’ (100 pmol; Life Technologies, Paisley, UK) and Poly(dI-
dC).Poly(dI-dC) (2 µg; Sigma-Aldrich) for 30 min at room temperature in binding buffer 
containing 4% (v/v) glycerol, 0.1 mg/ml nuclease-free BSA, 1 mM EDTA, 5 mM DTT, 100 mM 
NaCl and 10 mM Tris-HCl, pH 7.5 (20 µl). After incubation, the mixtures were 
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electrophoresed on native 15% polyacrylamide gels. The gels were transferred onto 1 µm 
pore size nitrocellulose membranes in 1 x TBE for 30 min at 380 mA, 100 V and then cross-
linked under UV light for 10 min. A Chemiluminescent Nucleic Acid Detection Kit (Pierce, 
Fisher Scientific UK, Leicestershire) was used to detect the SLPI:DNA complexes which were 
analysed using the Syngene G:Box and GeneSnap software. 
 
LPS binding assay 
Binding of recombinant SLPI-WT and SLPI-A16G and SLPI-S15G-A16G variants to P. 
aeruginosa LPS was assessed by indirect ELISA as previously described with some minor 
modifications 10,33. Briefly, Greiner® high binding 96 well plates were coated with serial 
dilutions (in serum-free medium) of recombinant SLPI-WT, SLPI-A16G and SLPI-S15G-A16G 
variants. Blank wells were coated with diluent alone. The plate was incubated at 37°C for 2 h 
and then washed three times with PBS containing 0.05% (v/v) Tween 20. The plate was 
blocked for 1 h at room temperature with 200 µl of 1% (w/v) BSA PBS containing 0.05% (v/v) 
Tween 20 per well. Biotinylated P. aeruginosa LPS (100 ng) was then added to each well and 
the plate was incubated at 37°C for 3 h. The plate was washed three times before addition of 
100 µl per well of streptavidin-conjugated HRP (1:2,500 dilution). After incubation at room 
temperature for 20 min, the plate was washed and ABTS single solution substrate (Life 
Technologies, Paisley, UK) was added. The absorbance at 405 nm of the wells was measured 
on a Biotek Synergy HT plate reader and data presented for each SLPI protein are corrected 
with the background absorbance readings obtained from wells coated with diluent only. 
 
Cystic fibrosis sputum and study approval 
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Sputum from Pseudomonas infected CF patients was obtained anonymously from the adult 
CF Centre at Belfast City Hospital. Sputum samples were in excess to requirements for 
diagnostic purposes. Permission to use sputum samples, which would have been disposed 
of, for validation purposes was given by the Director of R&D, Belfast Health and Social Care 
Trust. Sputum was frozen immediately at − 80 °C and used the next day after thawing at 
room temperature. 
 
Western blot analysis of recombinant SLPI incubated with CF sputum and NE  
Each purified SLPI protein (100 ng) was incubated with 10 µl of pooled Pseudomonas-
positive CF sputum or 2,500 ng of NE in Tris-buffered saline (total volume of 20 µl) for 8 h at 
37°C as previously described 10. Samples were separated by denaturing SDS-PAGE using 15% 
polyacrylamide gels and blotted onto nitrocellulose membrane. Membranes were probed 
using biotinylated anti-SLPI antibody as described above, visualised and individual SLPI bands 
were analysed by densitometry using the Syngene G:Box and GeneSnap software. 
 
Effect of SLPI-WT and SLPI-A16G in an in vivo model of pulmonary infection 
Housing and experimentation was carried out in accordance with the Animal (Scientific 
Procedures) Act 1986 and current guidelines approved by the Queen’s University Ethical 
Review Committee. A log phase culture of clinical strain of P. aeruginosa (PA Q502) isolated 
from the lungs of a CF patient was washed and suspended in sterile endotoxin-free PBS 
(Sigma-Aldrich) at an OD (600 nm) of 0.5, equating to 3 x108 CFU. C57BL/6 mice purchased 
from Charles Rivers Laboratories were anaesthetized and intranasally inoculated with 20 µl 
of PA Q502 or saline control. Concurrently, 100 µg of SLPI-WT and SLPI-A16G (or saline 
control) was administered intraperitoneally.  Animals were sacrificed 24 h post infection. The 
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animals were exsanguinated by cardiac puncture; the blood was coagulated at room 
temperature then centrifuged at 13,000 x g for 10 min. Sera was stored at -20oC until 
required for analysis. KC was quantified by ELISA (R&D Systems, Abingdon, UK) following the 
manufacturer’s instructions. 
Perfused, minced lungs were incubated in Iscove’s Modified Dulbecco’s Medium 
(IMDM) containing 1 mg/ml of Collagenase D and 200 µg/ml of DNase for 1 h at 37C, 200 x 
g. The tissue was then passed through a 70 µm cell strainer resulting in a single cell 
suspension. The cells were washed with sterile PBS and red blood cells were lysed with 3 ml 
of ACK lysis buffer (NH4Cl 8.3g/L, KHCO3 1g/L, 3.72g/L EDTA in distilled water).  The cells 
were counted and incubated with Fc block (1:1000 in PBS, eBioscience, Hatfield, UK) for 15 
minutes. The cells were stained for flow cytometry with CD45 FITC (1:1000 in PBS, 
BioLegend), CD11b APC (1:1000 in PBS, eBioscience), Gr1 PE (1:1000 in PBS, eBioscience), 
F4/80 PeCy7 (1:500 in PBS, eBioscience) for 20 minutes in the dark at room temperature. 
Cells were then washed and acquired using a FACSCanto II (BD Biosciences, Oxford, UK).  The 
data was analysed using FlowJo software (Tree Star). 
Statistical analysis 
All data were analysed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA) 
and are reported as mean ± SEM or median (IQR) where appropriate. Results are 
representative of n = 3 unless otherwise indicated. Means were compared by unpaired t-
test, Mann Whitney test, one-way analysis of variance (ANOVA) or Kruskal-Wallis test as 
appropriate. P < 0.05 was accepted to indicate statistical significance.  
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Supplementary Figures  
Supplementary Figure 1: Effect of SLPI-WT and SLPI-AG on lung cytokine and chemokines 
levels in a mouse model of Pseudomonas aeruginosa infection. C57BL/6 mice received an 
intranasal administration of saline or P. aeruginosa Q502 (PA), in combination with 
intraperitoneal saline, SLPI-WT or SLPI-A16G (n = 5 /group). After 24 h, levels of MIP-2, IL-1, 
TNF, KC and IL-6 were measured in lung homogenate by ELISA. 
 
Supplementary Figure 2: Effect of SLPI-WT and SLPI-AG on serum cytokine and chemokines 
levels in a mouse model of Pseudomonas aeruginosa infection. C57BL/6 mice received an 
intranasal administration of saline or P. aeruginosa Q502 (PA), in combination with 
intraperitoneal saline, SLPI-WT or SLPI-A16G (n = 5 /group). After 24 h, levels of MIP-2, IL-1 
and IL-6 were measured in serum by ELISA. 
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Figure Legends 
Figure 1. Mutation of neutrophil elastase cleavage sites in recombinant SLPI. (A) The 
relative amino acid frequency at the P1 position of neutrophil elastase (NE) cleavage sites 
identified in human SLPI 10 was determined using the MEROPS database 24. Gly was selected 
to replace the Ser 15 and Ala16 residues at the P1 position in the cleavage sites of SLPI by NE 
as Gly is rarely found at the P1 position of NE substrates. (B) The positions of NE cleavage 
sites in SLPI are indicated by the arrows between Ser15-Ala16 and between Ala16-Gln17.  The 
cleavage sites were mutated to Gly16-Gln17 for SLPI-A16G and Gly15-Gly16 for SLPI-S15G-A16G. 
The mutations are indicated in underlined bold type. 
 
Figure 2. SDS-PAGE analysis of purified SLPI-WT, SLPI-A16G and SLPI-S15G-A16G. SLPI 
variants were expressed as N-terminal His6-tagged recombinant proteins within the pQE30 
expression vector in M15 [pREP4] E. coli and purified by immobilized metal ion affinity 
chromatography. Purified SLPI-WT, SLPI-A16G and SLPI-S15G-A16G variants were analysed 
by SDS-PAGE on 15% (w/v) SDS-PAGE gels under reducing Laemmli conditions. (A) Gels were 
stained with Coomassie Brilliant blue for total protein analysis. (B) Proteins were transferred 
onto nitrocellulose membrane and SLPI detected with a biotinylated anti-SLPI antibody. (C) 
Proteins were transferred onto nitrocellulose membrane and SLPI detected with a rabbit 
anti-His tag antibody. 
 
Figure 3. Binding of SLPI and the SLPI variants to DNA. SLPI-WT, SLPI-A16G and SLPI-S15G-
A16G (1 μg) were incubated with a biotinylated consensus NF-κB DNA oligonucleotide, 
electrophoresed on a 15% polyacrylamide gel and transferred onto nitrocellulose 
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membrane. SLPI:NF-κB oligonucleotide complexes were detected by incubating the blot with 
streptavidin-HRP and visualised using a chemiluminescent substrate. 
 
Figure 4. LPS binding properties of SLPI variants. Serial dilutions of SLPI-WT, SLPI-A16G and 
SLPI-S15G-A16G variants were analysed via ELISA to determine the relative LPS binding 
properties of the purified proteins. Biotinylated Pseudomonas aeruginosa LPS bound to SLPI 
was calculated as the increase in absorbance at 405 nm. Data presented for each SLPI 
protein are corrected with the background absorbance readings obtained from wells coated 
with diluent only. 
 
Figure 5. Susceptibility of purified SLPI to cystic fibrosis sputum and neutrophil elastase 
proteolytic cleavage. Recombinant SLPI-WT, SLPI-A16G and SLPI-S15G-A16G were incubated 
with a (A) 10-fold molar excess of NE or (B) pooled CF sputum for 8 hours at 37°C. Samples 
were analysed by SDS-PAGE and Western blotting with an anti-His tag antibody. Each result 
for (C) NE and (D) CF sputum were analysed by densitometry. 
 
Figure 6. SLPI-A16G attenuates pulmonary neutrophil infiltration in a mouse model of 
Pseudomonas aeruginosa infection. C57BL/6 mice received an intranasal administration of 
saline or P. aeruginosa Q502 (PA), in combination with intraperitoneal saline, SLPI-WT or 
SLPI-A16G (n = 5 /group). After 24 h, (A) pulmonary neutrophil counts were characterised by 
flow cytometry as CD11b+Gr1+ and (B) serum KC levels were quantified by ELISA. *P < 0.05; 
**P < 0.01 versus PA. 
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Table 1. Primers used for the cloning of SLPI-WT into the pQE30 expression vector and for 
the preparation of SLPI-A16G and SLPI-S15G-A16G by site-directed mutagenesis.  
Primer DNA sequence Primer  name 
TTTTTTGGATCCGGAAAGTCCTTCAAAGCTGGAGTCTGTC SLPI-WT BamHI forward 
TTTTTTAAGCTTATGCTTTCACAGGGGAAACGCAGGATTTCC SLPI-WT HindIII reverse 
GGAGTCTGTCCTCCTAAGAAATCTGGTCAGTGCCTTAGATAC
AAGAAACCTG 
SLPI-A16G forward 
CAGGTTTCTTGTATCTAAGGCACTGACCAGATTTCTTAGGAG
GACAGACTCC 
SLPI-A16G reverse 
GGAGTCTGTCCTCCTAAGAAAGGTGGCCAGTGCCTTAGATAC
AAGAAACCTG 
SLPI-S15G-A16G forward 
CAGGTTTCTTGTATCTAAGGCACTGGCCACCTTTCTTAGGAGG
ACAGACTCC 
SLPI-S15G-A16G reverse 
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Supplement Figure 2
